At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 300 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Asian, Multicenter, Randomized, Double-blind, Placebo-controlled, 14-week Study of Mirogabalin in Participants With Central Neuropathic Pain Followed by a 52-week, Open-label Extension
In Brief
A Phase 3 clinical trial evaluating Placebo and Mirogabalin for Central Neuropathic Pain. Completed, enrolled 300 participants across 118 sites in 3 countries.
Detailed Summary
Investigate the efficacy and safety of mirogabalin in participants with central neuropathic pain in comparison to placebo
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCentral Neuropathic Pain
CountriesJapan, South Korea, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartMar 2019
First PostedApr 2019
Primary CompletionDec 2020
TodayJul 2026
First PostedApr 3, 2019
Enrollment StartMar 12, 2019
Primary CompletionDec 28, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.2 years ago
Interventions
Placebodrug
Matching placebo tablets for oral administration
Mirogabalindrug
Mirogabalin tablets for oral administration